Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Predictors of In-Hospital Death in Patients with Lung Cancer Admitted for Acute Radiation Pneumonitis: A Healthcare Cost and Utilization Project (HCUP) AnalysisClinical Lung Cancer.  22:e716-e722. 2021
2020 Survival in Patients with Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility QuotientJournal of Clinical Oncology.  38:3773-3784. 2020
2020 Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma GrowthFrontiers in Genetics.  11. 2020
2020 Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survivalNeuro-Oncology.  22:1359-1367. 2020
2020 Reduced Margin Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancers.Cureus.  12:e8618. 2020
2020 Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today 2020
2019 Metastatic, Triple-Negative, Androgen Receptor-Positive, Invasive Lobular Carcinoma of the Breast: A Case Report 2019
2019 Electromagnetic Transponder Based Tracking and Gating in the Radiotherapeutic Treatment of Thoracic MalignanciesPractical Radiation Oncology.  9:456-464. 2019
2019 A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neckOral Oncology.  90:80-86. 2019
2019 Longitudinal assessment of anchored transponder migration following lung stereotactic body radiation therapyJournal of Applied Clinical Medical Physics.  20:17-22. 2019
2019 Treatment intensity in locoregionally advanced head and neck cancer: Recent investigation leads to new questionsTranslational cancer research.  8:S188-S194. 2019
2018 Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation studyJournal of Neuro-Oncology.  140:341-349. 2018
2018 The Evolving Role of Postmastectomy Radiation TherapySurgical Clinics of North America.  98:801-817. 2018
2018 Hospice care, cancer-directed therapy, and Medicare expenditures among older patients dying with malignant brain tumorsNeuro-Oncology.  20:986-993. 2018
2018 A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer 2018
2018 Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative 2018
2018 Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis 2018
2018 Postmastectomy Radiation Therapy: Are We Ready to Individualize Radiation?International Journal of Breast Cancer.  2018. 2018
2016 Changes in neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios during chemoradiation predict for survival and pathologic complete response in trimodality esophageal cancer patientsJournal of Gastrointestinal Oncology.  7:189-195. 2016
2016 What predicts early volumetric edema increase following stereotactic radiosurgery for brain metastases?Journal of Neuro-Oncology.  127:303-311. 2016
2015 Pelvic local recurrence in a patient with muscle-invasive bladder cancer treated with interstitial thermal therapy and interstitial brachytherapyPractical Radiation Oncology.  5:e483-e487. 2015
2015 Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality TherapyJournal of Gastrointestinal Cancer.  46:131-137. 2015
2015 Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancerDiseases of the Esophagus.  28:619-625. 2015
2014 Stereotactic radiotherapy using tomotherapy for early-stage non-small cell lung carcinoma: Analysis of intrafraction tumour motion 2014
2014 BM-13 * THE (F)UTILITY OF PREDICTIVE MODELSNeuro-Oncology.  16:v34-v35. 2014
2014 Strategies to prevent brain metastasis in high-risk non-small-cell lung cancer: Lessons learned from a randomized study of maintenance temozolomide versus observationClinical Lung Cancer.  15:433-440. 2014
2014 Adjuvant chemoradiation for pancreatic cancer: What does the evidence tell us?Journal of Gastrointestinal Oncology.  5:166-177. 2014
2014 Potential of glyburide to reduce intracerebral edema in brain metastases 2014

Investigator On

  • A Phase II Study of Durvalumab (MEDI 4736) with Radiotherapy for the adjuvant treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma  awarded by University of North Carolina at Chapel Hill
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect  awarded by University of Wisconsin-Madison
  • Private Grant  awarded by NOVOCURE, INC.
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • RAD 2001 (2012-0825): Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER)
  • TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progession  awarded by Duke University
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • XUAB 17109-TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progression  awarded by Johns Hopkins University
  • XUAB2107-A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)  awarded by HOOSIER CANCER RESEARCH NETWORK
  • Full Name

  • Drexell Boggs